Off-the-Shelf cell therapy takes on tough blood cancers
NCT ID NCT05020678
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing an experimental therapy called NKX019 for people with certain blood cancers (like lymphoma and leukemia) that have come back or not responded to standard treatments. NKX019 uses donor immune cells (natural killer cells) that are engineered to find and attack cancer cells. The study will enroll about 150 participants to check safety and find the best dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NKX019 (a type of immune cell called a natural killer cell, engineered to target cancer cells)
What this could lead to
If it works, this could provide a new, off-the-shelf cell therapy option for people with hard-to-treat B-cell cancers, potentially with fewer side effects than current treatments.
What could go wrong
This is an early Phase 1 trial, so the main goal is safety, not yet proof of effectiveness. The therapy may not work for everyone, and there could be unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Colorado Blood Cancer Institute
Denver, Colorado, 80218, United States
-
Institute of Haematology, Royal Prince Alfred Hospital
Camperdown, New South Wales, 2050, Australia
-
Peter MacCallum Cancer Center
Melbourne, Victoria, 3000, Australia
-
Royal Brisbane and Woman's Hospital
Brisbane, Queensland, 4029, Australia
-
St. Vincent's Hospital
Sydney, New South Wales, 2010, Australia
-
The Cleveland Clinic Foundation
Cleveland, Ohio, 44195, United States